Page 86 - Read Online
P. 86

Kurt et al. J Cancer Metastasis Treat 2019;5:8  I  http://dx.doi.org/10.20517/2394-4722.2018.80                                  Page 3 of 6






























                                      Figure 1. Macroscopic image of the tumor located in the right ovary

               and genital structures, pelvic structures, organs of the upper abdomen were in normal appearance. Frozen
               examination of the mass from the right adnexal region was reported as malignant metastatic tumor. Due to
               this result staging surgery was performed.


               The paraffin sections of the removed mass were examined by our pathology department and the diagnosis
               of metastatic carcinoma at the right ovary was confirmed (Figure 2: the microscopic image of the metastatic
               tumor located at the right ovary). The morphology of the metastatic tumor was reported as lobular
               carcinoma and it was concurrently examined with the histopathology of the previously removed excisional
               biopsy material from the right breast. After the examination, the ovarian mass was diagnosed as a metastasis
               of the primary breast cancer. The immunohistochemical findings at the ovarian tumor are as follows: ER
               positive, PR negative, Pax8 negative, Wilms’ tumor 1 negative, gross cystic disease fluid protein-15 focal
               positive, GATA3 positive, epithelial membrane antigen positive, Ber-Ep4 positive; these findings supported
               the diagnosis for a malignant epithelial tumor but excluded a primary ovarian carcinoma. The lesion at the
               right breast, which appeared as a single focal lesion in imaging studies, was removed with clear margins.
               Therefore, no secondary surgery for local control was considered. After the abdominal surgery, the patient
               received the following chemotherapy treatments: 8 cycles of herceptin and docetaxel and subsequently
               8 cycles of trastuzumab and pertuzumab. She undergoes examination every three months and has been
               disease - free for 12 months as this report is written.


               DISCUSSION
               At the present day, more patients are diagnosed with microinvasive breast cancer due to the broad usage
               of mammography. Most of the microinvasive breast cancer cases (80%) do not have palpable masses in the
                                                      [2]
               breast and are diagnosed with mammography . Nevertheless, microinvasive breast cancers constitute only
                                                                                                        [1]
               a small part of invasive breast cancers (0.7%-2.4%) and confusion is still present about their prognosis .
               According to many studies, microinvasive breast cancers are reviewed in a spectrum between the
               early invasive breast cancer and in situ carcinoma of the breast, and excellent survival expectations are
                      [1-4]
               reported . However, in some cases, local and distant recurrences are reported during follow-up despite this
                                       [5,6]
               high prognostic expectation . Involvement of axillary lymph nodes, which is a very important prognostic
               factor during the treatment and follow-up of breast cancers, is reported to be between 0 and 25 percent of
                                            [3]
               microinvasive breast cancer cases . Involvement of axillary lymph nodes is crucial regarding local and
   81   82   83   84   85   86   87   88   89   90   91